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ABSTRACT 
Introduction 
Cancer breast is the leading cause of site specific cancer related  death 
next to cancer cervix for women aged 20-59 years. Early diagnosis and 
treatment will reduce the morbidity and mortality of the disease  and thus it 
prolongs the survival of the patient .The patient clinically presented in the late 
stage of disease , due to the lack of knowledge and the ignorance of the patient.  
Now due to the routine screening mammography in women done after 50 
years, it reduces the mortality 0f about 33%. By self breast examination 50-75 
% of cancer can be detected easily. I made an attempt to study about operable 
carcinoma breast in various aspects. 
Aim and objectives 
To study the various type of clinical and pathological patterns of 
presentation  of operable carcinoma breast in Government Royapettah  Hospital 
. To decide the  institutional  treatment protocol and to minimize the breast 
mutilation surgery. 
Key Words: 
 Operable carcinoma breast, self breast examination, breast conservation 
surgery, sentinel node biopsy, multy modality  management. 
Methods and Materials 
 A prospective study  conducted in   50 patient ,those are all admitted in 
Government Royapettah hospital from January 2013 to November 
2013.Detailed history ,clinical examination, investigation done to arrive a final 
diagnosis and plan treatment according to the stage. 
Results 
50  patients of patients were studied during the study period , the average 
age of occurrence of operable carcinoma breast is 48.54 years. One patient 
having positive  family  history. Mostly  occurring  in  patient with early 
menarche. Lump ( 100%) is the most commonest presentation. 98% of  the 
studied patient  having  IDL as HPE report . In my study population 56 % of 
them in stage II disease. 
Conclusion 
The incidence of operable carcinoma breast is more common among 
middle aged groups. The most commonest  presenting  compliant is lump and 
most commonest histopathological   type is infiltrating  ductal  carcinoma. 
Multimodality modality manage is the optimum treatment adopted. 
Routine screening mammography and by the  health awareness 
programme  carcinoma breast , now-a days , detected  at an  earlier st age.  
 
1INTRODUCTION
The commonest cause of death in adult women is carcinoma breast and
it is the most commonest  leading cause of death among aged 20-59 years.
High socio economic status will increase the incidence of carcinoma breast.
.Now it is reported in younger age group also.
Early diagnosis  and treatment will decrease the morbidity and
mortality of the disease significantly .  The treatment depends upon the
patient at which stage they are presenting to the health services. Screening
mammography above 50 years , if used as a routine will reduce the mortality
from cancer by 33%. If they are diagnosed early,   the breast conservation
surgery can be planned. If the patient present at the advanced stage, they have
to be treated aggressively having severe complication after treatment. The
breast cancer management   requires a multi  modality approach, which
includes surgery ,radiotherapy, chemotherapy.
In this study an attempt  to study those patient who are eligible for
surgery ie. Operable carcinoma breast.  It  includes   both early breast
cancer patient ( stage 1, stage 11A, 11B) and Operable  LABC  patients
(111A , Stage 111B ) either  directly  taken  for  surgery  or after neoadjuvant
they are eligible for surgery.
2In this dissertation an attempt is made to study the various risk factors,
natural history of disease, clinical features,  stage of presentation, correlation
of FNAC with  post  operative  histopathological report ,hormonal receptor
status and management o f opesrable carcinoma breast.
3AIM AND OBJECTIVES
To study the various type of clinical and pathological patterns of
presentation of operable carcinoma breast in Government  Royapettah
Hospital.
To decide the relavent  institutional   treatment protocol  and to
minimize the breast mutilation surgery.
4REVIEW OF LITERATURE
HISTROY
The earliest known document to refer to breast cancer is the smith
surgical papyrus (3000- 2500 BC) . The author concludes that “ There is no
treatment “ ,in reference to this cancer. Radical Mastectomy surgery was
reported by Halsted and Meyer ,in 1894 they demonstrated that good loco
regional  cure is achieved.
Modified Radical Mastectomy was advocated by  Patey and Dayson in
1948, for the management of advanced operable breast cancer.
Madden advocated a Modified Radical mastectomy , preservation of
pectoralis major and minor muscle . And this approach prevents the clearance
of (level 111 ) apical  axillary  lymph nodes.
There was a transition from Halsted Radical Mastectomy to Modified
Radical Mastectomy and that was used as a most frequently used procedure
since 1980.
To control the loco regional  disease , integration of surgery ,RT , CT
was made since 1970.
5ANATOMY OF BREAST
GROSS
Breast forms an important secondary sexual organ in female and it
provides nutrition to the new born.
SITUATION
The breast rest over the superficial fascia of pectoral  region , and
axillary tail , which is a small extension pierces the deep fascia and it lies in
the axilla..
EXTEND
          Vertically - 2 nd to 4 th rib .
           Horizontally-lateral border of  sternum  to the mid axillary line.
6DEEP RELATION
It rest on the deep fascia covering the pectoralis  major. Deep to the
fascia are the three muscles, namely the  pectoralis major , serratus  anterior ,
external oblique muscle of abdomen. The loose areola tissue , which lies
between the breast and deep fascia called “sub mammary space “. This allows
the breast to move freely over the fascia.
STRUCTURE OF THE BREAST
It is divided into the skin, the parenchyma and the stroma. The skin is
further divided into nipple and areola.
NIPPLE
 It is a conical projection just below the centre of the breast at the level
of 5th ICS. It is rich in nerve supply and many sensory end organ terminates
at the end of nerve fibres.
AREOLA
Circular pigmented area of the skin  surrounding  the nipple is called
areola . This region is having   a modified sebaceous  gland ,which is
enlarged  during pregnancy and lactation  enlarged , to form raised  tubercle
of Montgomery.
7PARENCHYMA
It is made up of glandular   tissue , which secretes milk. The gland
consist of 15-20 lobes , each lobe is a cluster of alveoli, and it is drained by
lactiferous duct. The lactiferous duct coming towards the nipple and open it
near its terminal, it dilates to form lactiferous sinus.
THE STROMA
The supporting frame work was on the gland is stroma. It is partly
made up of fibrous and fatty tissue .The skin and the gland is anchored to the
pectoral fascia by the fibrous tissue in the form of septa , known as the
suspensory  ligament of coopers. The main bulk is formed by the fatty tissue ,
distributed all over breast , except behind the nipple areola complex.
Axillary  tail  of  spence
It is the prolongation of outer  part of the gland . Through foramen of
larger, an opening in the deep fascia ,it extent into the axilla.
BLOOD SUPPLY
ARTERIAL SUPPLY
The gland is highly  vascular , except in its posterior part which is a
vascular.
8Axillary  artery supplies the gland through its branches like superior
thoracic, acromio thoracic and lateral thoracic artery.
Antero medial part of gland  supplied by internal thoracic artery
through its perforating branches.
Antero lateral part of gland supplied by 2nd  to  4th intercostals artery
through its perforating branches. . The 2nd intercostals perforators is the
largest one among the rest.
The skin is supplied medially by anterior intercostal arteries , laterally
by lateral thoracic artery  a branch of axillary artery and lateral cutaneous
branches of posterior intercostals arteries.
VENOUS DRAINAGE
The venous drainage of the breast follows the corresponding arteries.
They all converge towards the nipple to form a anastomotic venous circle ,
from there it forms the superficial  and deep veins .The posterior intercostal
vein drains the breast communicate with vertebral veins , by this the
metastasis reach the bones without lung involvement.
9NERVE SUPPLY
Anterior and lateral cutaneous of the 4th to 6th intercostals nerve gives
the sensory and sympathetic supply to the breast. Ovarian and Hypophyseal
hormones  controls the secretory activity of breast .
LYMPHATIC DRAINAGE OF BREAST
The principle nodal drainage of the breast are the axillary and internal
mammary group of lymph node.
75% of the lymphatic drains into the  Axillary lymph nodes. They are
pectoral, subscapular, lateral , central and apical nodes.
25% of  the lymphatic drainage through internal mammary nodes.
10
Other nodes draining are Supra clavicular nodes, Cephlic nodes,
posterior nodes in front of head of ribs, sub diaphragmatic and subperiosteal
lymph plexus.
The Subareolar plexus of sappy ,  a plexus of lymph vessels present
deep to areola receives the lymphatic drainage from parenchyma of breast ,
drains into anterior axillary nodes.
Levels of Lymph nodes
The levels are divided into 3 levels depending upon the relation to the
pectoralis  minor  smuscle.
Level I nodes-below and lateral to pectoralis minor muscle .
Level II nodes-deep to pectoralis minor, interpectoral nodes called
Rotters nodes.
Level III nodes –above and medial  to pectoralis minor .
HISTOLOGY OF BREAST
The mature breast consist of 3 type of principle tissue. They are
glandular epithelium ,fibrous stroma and supporting tissue and the adipose
tissue .The glandular system consist of branching system of ducts , end in
terminal ductules or acini. These acini  are the milk forming glands in the
lactating breast called as lobule.
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The ductal system is lined by columnar epithelium surrounded by
myoepithelial cells, a basement membrane and surrounding elastic fibers. The
basement membrane layer forms the important boundary in differenciating
the in situ  from invasive  carcinoma. If the basement membrane is intact
called as  carcinoma  in situ.  Involvement of basement membrane by
malignant cells and invading the stroma called Invasive breast carcinoma.
CARCINOMA BREAST
RISK FACTOR
Age
Carcinoma breast is very rare below the age of 20 years, after that the
incidence  steadily increases, and by the age of 90 years 20% of womens
affected.
Sex
Less than 0.5% of males are affected by carcinoma breast.
Family history
There is increase in likelyhood of patients  with strong family  histroy
of carcinoma breast, ovarian and colonic cancer.
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Genetic Factor
It  accounts for 5-10% of all breast cancer cases. 40% other   cases due
to mutation in BRCA 1 and BRCA 2 ,and others are  HER2 mutation and P
53 mutation . Genetic counselling and DNA testing can identify the high risk
cases .80% of chance of developing breast cancer.
Diet
There is increased risk of developing carcinoma breast with diet less in
phytoestrogen and increase in alcohol intake.
Menstural Cycle
Early menarche and late child birth associated with increased risk of
carcinoma breast . Pregnancy at early age and multiple pregnancy having a
protective role in carcinoma breast .
Endocrine
Endogenous hormones
Increased risk of oestrogen increased risk of carcinoma breast ,so
common in nulliparous women.
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Exogenous hormones
HRT- long term use of oestrogen increases the risk of carcinoma
breast. Diethylstilbesterol  usage increases the risk of carcinoma breast.
Other risk factor-Radiation exposure, obesity.
Histological risk factor
Proliferative Breast disease,  atypical ductal hyperplasia, atypical
lobule hyperplasia, lobular carcinoma in situ.
Pathology
Carcinoma arising from milk duct called ductal carcinoma, and  from
lobule called lobular carcinoma. It is divided into in situ or invasive
carcinoma, depending upon the  basement membrane involvement.
Depending upon the degree of differenciation  it is divided into 3 grades.
Well differenciated- resembling like normal  breast tissue , moderatively
differenciated and poorly differenciated.
Current nomenclature
Ductal carcinoma is  the most commonest one, accounts for 50-70% of
invasive breast cancer. But  lobular carcinoma accounts for 10% of breast
cancer. Subtype  of classical type of lobular carcinoma carries better
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prognosis than pleomorphic type. Invasive lobular carcinoma is commonly
bilateral and multifocal.
Mucinous or colloid tumours which produces abundant of mucin
accounts for 2-3% of cases. The Medullary  carcinoma with solid sheets of
large cells and with marked lymphocytic reaction accounts for 5% of breast
cancer.
Inflammatory carcinoma is a rare variety, highly aggressive cancer,
they present as a painful ,swollen breast , which is warm with cutaneous
oedema. It involves at least 1/3 rd of breast . The cutaneous oedema is due to
blockage of subdermal lymphatics with carcinoma cells. It mimics a breast
abcess. A breast biopsy will confirm the diagnosis and shows undiffenciated
cancer cells .
In situ cancer is a non invasive cancer, in that the basement membrane
is intact .  Nowadays ,due to advent of mammography screening , 20% of
insitu carcinoma can be detected easily. Insitu carcinoma may  be ductal or
lobular carcinoma. Insitu carcinoma may be multifocal and bilateral ,20% of
cases will develop invasive cancers.
DCIS ,classified by VanNuy’s system include the patients age, type of
DCIS , presence of microcalcification , size of the disease and extend of
resected margin .Patient with low grade disease , complete excision of
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tumour is necessary , no further treatment needed. Patient with high grade ,
need radiotherapy after excision. Though it is a  overt treatment, mastectomy
is curative .
If the treatment is stained with estrogen and progesterone ,now it is
done as a routine one and this presence indicates the use of adjuvant
hormonal theraphy with tamoxifen .Tumours stained with HER2 receptors ,
patient was treated with monoclonal antibodies , commonly used is
trastuzumab. The pathologist took part in deciding which adjuvant therapies
will be appropriate.
SPREAD OF DISEASE
1. Local spread
2. Lymphatic spread
3. Blood spread
Local spread
By this method , the tumour invades the other part of breast .It also
invade skin , pectoralis major  and the chest wall. Involvement  into the skin
causes dimpling of the skin, invasion  of coopers ligament results in tethering
of  the skin.  Peau d’ orange appears as a result of dermal lymphatic invasion
by tumour cells.
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Deeply it involves pectoralis major , chest wall and serratus anterior
muscle.
Lymphatic spread
Lymphatic metastasis  to  axillary lymph node and  the internal
mammary lymph nodes. By  tumour emboli  and  permeation  the  spread
will occurs. The group of  lymph node involvement depends upon the site of
tumour in breast tissue .From axillary lymph nodes it spreads to
supraclavicular lymph nodes by retrograde manner.the incidence of axillary
nodal  involvement ,in relation with size of the tumour are the following  <
2cm -, 30%, 2-5 cm-35% and > 5 cm -50%.
The supraclavicular  node involvement indicates the disease is very
extensive and  having poor prognosis .By sub peritoneal lymphatic plexes it
spreads to liver.
Blood spread
Spine is the most commonest site of metastasis from breast cancer,
through batson plexes of vein.The lumbar vertebra , femur, thoracic vertebra ,
ribs and skull are the following occurs in order, and these deposits are
osteolytic. It  also spreads to liver, lung, pleura, adrenals,ovaries ,brain and
skeletal system. Through transcoelomic spread it spreads to ovaries .(
Krukenberg’s tumour)
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Examination of breast
Self breast examination
Above 25 years should perform self breast examination.
After the completion of menstruation. Should be done in lying down position
with a pillow under the shoulder.
Age, socioeconomic status
History
? Lump, .pain ,nipple discharge ,nipple retraction
? History related to metastasis-bone pain ,dyspnoea, cough with
expectoration, jaundice.
? Past history-medical illness, previous surgery ,drugs ,OCP
? Menstrual and Marital history –age at menarche, age at first child birth,
parity, breast feeding, age at menopause
Carcinoma breast with skin involvement
Examination of axillary nodes
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? Family history-any breast, ovarian and uterine cancers
Local Examination of affected side
1. Patient  sitting ,Arm by the sides of body
2. Arms raised above the head
3. Leaning forward position
4. Lying position
5. Arms over the hips
Inspection
? Both breast –symmetry, shape ,size ,position, any  mass
? Nipple areolar complex-level of nipple,discharge ,retraction, ulceration
? Skin of breast-dilated veins, dimple, puckering, peau d’ orange,
retraction, nodule, ulceration, fungation peau d’ orange-oedema of skin
and deepening of the mouth of sweat gland , hair follicles,due to
obstruction of subdermal lymphatics.
Arm and thorax-Oedema ,nodule
? Cancer en cuirase-thickened skin and multiple cancerous nodules like a
coat of armour in arm and thorax
? Axilla and supraclavicular fossa-fullness
? Leaning forwards-fixity of chest wall
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Palpation
? Using the palmar aspect of hand with flat hand
? Four quadrants , axillary tail
? Local rise in temperature ,tenderness
? Lump- number, site, size, shape, surface, margins ,consistency, Fixity
to skin, intrinsic mobility ,fixity to muscle, chest wall
? Nipple –any tumour deep to nipple ,nipple discharge
? Examination of lymph nodes in axilla
? Anterior ,central , apical ,posterior and lateral groups
? Supraclavicular nodes
Percussion
? Over the sternum for internal mammary nodes
? Examination of other breast, opposite  axilla , supraclavicular fossa
? Examination of other system-Cardiovascular system
? Respiratory system-Pleural effusion
? Abdomen –Liver metastasis
? Skull, pelvis , vertebra,
? Pelvic  and per rectal examination
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Investigation
? Routine Investigations
? Urine –albumin, sugar , deposits
? Blood-Urea , sugar ,creatinine
? Blood-Hemoglobin ,complete hemogram
? Blood grouping and typing
? X ray chest
? ECG in all leads
? Liver Function test
II.Specific Investigations
                                                                   Clinical
Tripple assessment                                  Imaging
                                                                   Pathological
? Clinical -  Age
Examination
? Imaging - USG Breast
Mammography
? Pathological - FNAC
Tru-cut biopsy
99.9% of cases detected by this method confidently
21
USG of breast
? Safe non invasive method of investigation
? It is one of the essential part in triple assessment
? Used in young women < 40yrs with dense breast
? It differentiates solid and cystic swelling upto 0.5 cm lump
? Features of Malignancy-irregular margins, non compressibility,
irregular posterior Shadowing ,irregular internal echoes, smooth
margins with acoustic enhancement
MAMMOGRAPHY
? Plain x ray of soft tissue of breast
? Low voltage , high amplitude x rays
? Sensitivity increases as the age advances , with less dense breast
>40yrs
? Two views-Craniocaudal , Mediolateral oblique view
? it provides true positive rate of 90%
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Indication
? As a screening method > 50 yrs
? >40 yrs with high risk factors, with suspicious breast lump
? to find the multicentricity of affected side, if planned for BCS
? Opposide side for routine screening
? Mammograhic guided biopsy
? Follow up period ,after surgery
Features suggestive of cancer
? Solid  mass effect with or with out stellate features
? Asymmetric thickening of breast,   architectural distortion
? Clustered microcalcification
? Fine and stippled calcification, speculation.
Grading in Mammography
BI-RADS (Breast Imaging Reporting and Data System)
Grade I –Negative
Grade II-Benign lesion
Grade III-Probably benign lesion
Grade IV-Suspicious of malignancy
Grade V- Highly suggestive of malignancy
Grade VI- Known carcinoma
23
FINE NEEDLE ASPIRATION CYTOLOGY
? Routinely used in investigation of breast lump
? A 22 gauge needle is used
? High sensitivity 98% ,specificity 98% and positive predictive value 98
? Simple, quick ,Safe, less traumatic less cost effective
FNAC Scoring
i. C0 – No epithelial cells
ii. C1 –Scanty epithelial cells
iii. C2 –Benign cells
iv. C3 – Atypical cells
v. C4 – Suspicious of malignancy
vi . C5 –Malignant cells
True Cut Biopsy
? allows a  definitive preoperative diagnosis
? differentiate between ductal carcinoma insitu from invasive carcinoma
? it gives us about the receptor status
? it should be done before neoadjuvant therapy
24
MRI Breast
? useful to detect the recurrence
? used in patient with implants
? useful in lobular carcinoma to assess the multifocality and
multicentricity
? screening tool in high risk women.
? no radiation exposure
FOR Metastatic work up
X ray chest
? easy method to detect the lung metastasis
? it is visible only it reaches 2cm size
Bone X-ray
X-ray of spine ,end of long bones ( femur , humerus) and skull
osteolytic type of metastasis
USG abdomen- for liver metastasis , ascitis , krukenberg tumour
Bone scan – more accurate in detecting bony metastasis
PET Scan-useful in recurrence cases
25
Staging of carcinoma breast
TNM  Staging
 T staging  of the tumour
TX Primary tumour cannot be assessed
TO No evidence of primary tumour
Tis Carcinoma insitu
Tis(DCIS) Ductal carcinoma in situ
Tis (LCIS) Lobular carcinoma insitu
Tis(pagets) Paget disease of nipple with no tumour
T1 Tumour 2cm or less in greatest dimension
T1mic Microinvasion 0.1cm or less in greatest dimension
T1a Tumour more then 0.1cm but not more than 0.5cm in
greatest dimension
T1b Tumour  more  than  0.5cm  but  not  more  than  1cm  in
greatest dimension
T1c Tumour more than 1cm but not more than 2cm in greatest
dimension
T2 Tumour more than 2cm but not more than 5cm in greatest
dimension
T3 Tumour more than 5cm in greatest dimension
T4 Tumour of any size with direct extension to (a) chest wall
or (b) skin
T4a Extension to chest wall , not including pectoralis muscle
T4b Edema ( including Peaud’ orange ), or ulceration of the
skin of the breast , satellite skin nodules confined  to the
same breast
T4c Both T4a and T4b
T4d Inflammatory carcinoma
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Regional  lymph node staging
NX Regional lymph nodes cannot be assessed (eg .previously
removed)
NO No regional lymph node metastasis
N1 Metastasis to movable ipsilateral  axillary  lymph nodes (s)
N2 Metastasis in ipsilateral axillary lymph nodes fixed or matted , or
in clinically apparent ipsilateral internal mammary nodes in the
absence of clinically evident axillary lymph node metastasis
N2a Metastasis in ipsilateral axillary lymph nodes fixed to one another
(matted) or to other structures
N2b Metastasis only in clinically apparent ipsilateral internal
mammary nodes and in the absence of clinically evident axillary
lymph node metastasis
N3 Metastasis in ipsilateral infraclavicular lymph node(s) with or
without axillary lymph node involvement , or in clinically
apparent ipsilateral internal mammary lymph nodes(s) and in the
presence of clinically evident axillary lymph node metastasis ; or
metastasis in ipsilateral supraclavicular lymph node(s) with or
without axillary or internal mammary lymph node involvement
N3a Metastasis in ipsilateral infraclavicular lymph node(s)
N3b Metastasis in ipsilateral internal mammary lymph node (s) and
axillary lymph node(s)
N3c Metastasis in ipsilateral supraclavicular lymph node(s)
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Distant Metastasis
MX Distant metastasis cannot be assessed
MO No distant metastasis
M1 Distant metastasis
TNM Stage grouping
Stage 0 Tis NO MO
Stage 1 T1 NO MO
Stage11A TO N1 MO
T1 N1 MO
T2 NO MO
Stage11B T2 NO MO
T3 NO MO
Stage 111A TO N2 MO
T1 N2 MO
T2 N2 MO
T3 N1 MO
T3 N2 MO
Stage 111B T4 NO MO
T4 N1 MO
T4 N2 MO
Stage 111c Any T N3 MO
Stage1V Any T Any N M1
28
The Manchester system(1940)
Stage 1
The Tumour is confined to  breast tissue.  skin involvement is less than
the size of the tumour. NO lymph node  involvement.
Stage 11
Stage 1 with with  axillary lymph nodes which are mobile.
Stage 111
Tumour extends beyond the breast tissue , skin involvement is more
than the size of the tumor or ulceration .Tumour fixed to underlying structure.
Stage 1V:
Tumour involving the Chest wall , “cancer-en-cuirase”,  axillary nodes
are fixed, supraclavicular nodal involvement,inflammatory carcinoma breast
satellite nodules or distant metastasis .
Treatment of Carcinoma Breast
The main aim of treatment is to
1. To reduce the chance of local recurrence
2. To reduce the chance of metastasis.
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It needs a multimodality management.It depends upon the stage of
disease.In this dissertation we are dealing about operable carcinoma breast.
Operable breast cancer include early breast cancer and  operable
locally advanced breast cancer.
EARLY BREAST CARCINOMA-STAGE 1, STAGE 11A&11B
Aims of the treatment
1 to cure the disease but recurrence is  common later
2 local disease control in axilla and breast
3 preserve the function and structure
4 preventing or delaying the development of breast
cancer.
It includes surgery with or without  radiotherapy for   local disease and
chemotherapy and hormonal therapy for systemic therapy .
Surgery for early breast cancer:
1. BCS  ,SLND and radiotherapy to tumour bed
2. MRM with axillary dissection3.total mastectomy ,SLND followed by
axillary dissection if positive SLN
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Locally Advanced Breast Cancer
? It includes stage 111a, 111B &C
? Clinical presentation of LABC from Haagensen and Stout
? Large tumour >5cm
? direct involvement of skin oedma (peau d’ orange), chest wall,
ulceration
? supraclavicular involvement
? Inflammatory breast cancer
? LABCs are operable most of the time except 25-30% are inoperable
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Surgeries for local treatment
1. Breast conservation surgery(BCS)-
It is also called as wide local excision, lumpectomy ,segmental
mastectomy quadrantectoy, tylectomy and partial mastectomy.
Indication- well differenciated tumour ,mammographically detected
tumours, size of the tumour <4cm, No or N1 status patient.
Contraindication-Multicentricity ,pregnancy , persistant positive
margins ,central quadrant tumour,poorly differeciated tumour,Tumour size
>20-25% of breast volume ,Patient not willing for post operative
radiotherapy, collagen vascular disease ,.
Aim is to remove 1cm normal breast tissue along with
tumour.Removing the entire segment along with tumour is quadrantectomy.
It should be done along with sentinel node biopsy.
 Advantage- preserve the skin ,shape ,sensation and psychological effect .
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Sentinal node biopsy
It should be done in node negative patient. Preoperative localisation of
sentinel node by injecting patent blue dye and radioisotope labelled albumin
around the nipple in subdermal plexes. A hand held gamma camera can
identify the marker draining the primary site. If node is negative ,then no
need for axillary dissection.
Modified Radical Mastectomy
Indication- Multifocal disease, central quadrant tumour, large tumour,
patient preference ,local recurrence and tumour involving nipple.
Modified Radical ( Patey) mastectomy- removal of entire breast  with
tumour, large area of skin , nipple ,all fat, fascia,axillary lymph node. The
MRM surgery extends medially from midline of sternum laterally upto
Intra operative picture - showing 
long thoracic nerve 
Specimen of mastectomy with axilliary clearance
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anterior border of latissimus dorsi muscle.Superiorly it extends from clavicle
to inferiorly upto 2-3 cm inferior to inframammary fold
The structures to be preserved are axillary vein ,nerve to latissimus
dorsi and serratus anterior.Pectoralis minor muscle is divided or retracted.
Pectoralis major muscle  is preserved.
In Auchincloss type mastectomy pectoralis minor muscle is preserved.
Radiotherapy
Indication- patients with high risk of  local recurrence, large tumour,
many positive nodes and lymph vascular invasion.
? In patient undergoing BCS for local treatment of remaining breast
tissue. Dose of 45-50 Gy of whole body irradiation  as 2Gy/day ,5days
/week for 5 weeks and boost to tumour bed region.
Systemic treatment
Chemotherapy Hormonal therapy
? targeted upon micro metastasis and helps in delaying relapse and
increases the survival period.
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Chemotherapy
It is used as adjuvant or neoadjuvant chemotherapy .An anthracyclines
should included in this regimen. The regimens are 6 cycle of FAC ,CEF ,FEC
and CAF.
An adjuvant chemotherapy is for patient hormone receptor negative
,size of tumour <1cm and node positive tumour ,special type of tumours with
size >3cm.
In neoadjuvant chemotherapy , in case of LABC to reduce the size of
tumour ,make it operable .it gives 80% success in reducing the size of
tumour. It is given in both pre and post menopausal women with poor
prognosis, and those are having high risk of recurrence.
The local and regional cancer burden is decreased by neoadjuvant
used to evaluate the response of chemotherapy of the primary tumour and
nodal metastasis. The response to treatment can give the prognosis of disease.
If complete pathological response indicates good survival. If there is
progression of disease it indicates poor survival.
Primary anthracycline based chemotherapy should be Included in
patients with inoperable breast cancers ,and those with inflammatory breast
cancer and patients with ipsilateral internal mammary or supraclavicular
nodes .
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Chemotherapy  Regimens
1 CAF regimen
Cyclophosphomide
Doxorubicin
5-flurourocil
100mg/m 1-14days PO
30mgm/m 1&8 days
500mg/m2iv 1&8 days every 28 days
for 6 cycle
2 5-Flurouracil
Doxorubicin
Cyclophosphamide
500 mg/m2 IV 1&8 0r 1&4 days
50 mg/m IV day 1
500mg/m IV day 1 every 21 days for
6 cycles
3 AC regimen
Doxorubicin
Cyclophosphamide
60 mg/m IV day1
600 mgs /m IV day 1
every 21 days for 4cycles
4 FEC regimen
Cyclophosphamide
Epirubicin
5-Flurouracil
75 mg/m 1-14 days PO
6o mg/m IV 1&8 days
500 mg/m IV 1&8 days
Every 28 days for 6cycle
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Hormonal therapy
? it is used as an adjuvant therapy
? to reduce the risk of tumours  in opposite breast
Indication
? Tumour size 1-3 cm  , node  negative women with HR positive.
? Tumour size >3 cm  , node positive all women
? Stage IV breast cancer
Drugs
1. Tamoxifen-20mgs /day  (selective estrogen receptor modulator) for 5
years in premenopausal age group. Contraindicated  in postmenopausal
group, because of risk of endometrial carcinoma.
2. Aromatase  Inhibitors-indicated for postmenopausal age group.
Anti HER-2/neu Antibody therapy
Trastuzumab used in the treatment of HER-2/neu positive breast cancer
patient .
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Follow up of Breast cancer patient after surgery
1. Every 3-6 months for 3 years
2. Every 6-12 months for next 2 years and then annually
Investigation to be done
1. History regarding recurrence and metastasis
2. Physical examination, Breast self examination
3. Mammography –annually
4. Others –pelvic examination, complete blood count ,liver function test,
x-ray chest , CT-chest, USG abdomen and pelvis.
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MATERIALS AND METHOD
Source of data
This study is conducted in 50 patient admitted in Government
Royapetah Hospital
Study design
Cross sectional prospective study
Study period
Jan 2013 to oct 2013
Inclusion criteria
1. Patient aged between 20 to 80 yrs
2. All patients with breast lump with FNAC positive report
3. Patients who belongs to clinical stage I, stage II, stage III
Exclusion criteria
1. Patients with benign breast disease
2. Cases of breast cancer in males
3.  Exclude all inoperable advanced breast malignancy
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4. Patients with inflammatory breast carcinomas
5. Recurrent breast lump in a previously operated case of carcinoma
breast.
Sample size
? 50 patient with the mentioned above criteria
? After getting  informed consent
Method of collection of data
1. Detailed history taking
2. Complete clinical examination
3. Investigation
? Routine investigation
? complete blood count
? Blood sugar ,urea , creatinine
? urine routine
Specific investigation
? USG-breast and axilla
? Mammography
? X-ray chest
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? FNAC /Tru-cut biopsy
? Liver function test
? USG abdomen and pelvis
? Skeletal survey
? Electrocardiogram
? Receptor status done outside under the insurance
? Scheme
Treatment protocol
Patient with Early breast cancer underwent surgery followed by
adjuvant chemotherapy, hormonal therapy  and  radiotherapy.
Patient with stage III disease undergoes neoadjuvant chemotherapy
followed by surgery , then adjuvant chemotherapy, hormonal therapy,
radiotherapy.
Data computation
MS Excel 2010
Data analysis
Statistical analysis using percentages and frequencies
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Age Distribution
Age Class
Intervals Observations Percentages
21-30 3 6
31-40 8 16
41-50 23 46
51-60 11 22
61-70 4 8
71-80 1 2
Total 50 100
The distribution of age in my study  ranges people  from 21 -80 years.
The lowest age limit in      my study is 26   and the highest age limit is 80.
The mean age of presentation is  48.5 .Most of the patient belongs to 41-50
years  age group.
Age Observations
Number of Observations 50
Mean Age 48.54
Standard Deviation 10.54
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Presenting Symptoms
Presenting Symptoms
Most commonest presentation in my study groups  is lump (100%)
present in  and the next is pain (22%) about , others are nipple retraction
(18%) ,nipple discharge. Duration of Symptoms
Age Class Intervals Observations Percentages
Lump 50 100
Pain 11 22
Nipple Retraction 9 18
Nipple Discharge 1 2
Skin Dimpling 4 8
Peaud'orange 3 6
Skin Tethering 1 2
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Duration of Symptoms
Duration of Symptoms
In  my study about 26( 52%) of the patients presented  with  duration
of less than 2 months. About 16 (32%) patient presented with duration of 3-6
months and about 8(16%) of the  patient
Duration of
Symptoms Number of Observations Percentage
?2 months 26 52
3-6 months 16 32
7-12 months 8 16
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Co-morbid Conditions
In my study out of 50 patients 11(22 %) of them having  DM , 3(6%)
of  them  having  HT  ,and  11(22%)  of  patients  having  both  DM&  HT..This
shows DM and HT having  they are high risk factor for the development of
carcinoma breast.
Co-morbid conditions Number of Observations Percentage
Nil 28 56
Diabetes Mellitus 11 22
Hypertension 3 6
DM+HT 6 12
Hypothyroid 1 2
Hysterectomy 1 2
Total 50 100
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Diet History
Vegetarian
Non Vegetarian
Diet History
In our study people 45 (90%  )of them were nonvegetarian .This shows
a strong relationship between high dietary fat intake more  prone for
carcinoma breast .
Diet Number ofObservations Percentage
Vegetarian 5 10
Non Vegetarian 45 90
Total 50 100
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Age at Menarche
Age of menarche in
Years
Number of
patients Percentage
10 to 11 15 30
12 to 13 26 52
14 to 15 7 14
16 to 17 2 4
Total 50 100
In my study the age at menarche ranges from 10 - 17 years,   The
lowest age of menarche is 10years and the highest age at menarche is 17
years. The mean age of menarche is 12.44.Earlier the menarche more chance
of carcinoma breast.
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Menopause Status
Menopause
Status Number of Observations Percentage
1 5 10
2 13 26
3 32 64
Total 50 100
Out of 50 patient 31 of  them  post menopausal and 19 of them
perimenopausal. In this   study   post menopausal age group are more
susceptible for carcinoma breast.
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1, 2%
Marital Status
Married
Unmarried
Marital Status
Marital
Status Number of Observations Percentage
Married 49 2
Unmarried 1 98
Total 50 100
Out of 50 patient one of the patient (2%) was unmarried, remaining
were married.
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Age at Birth
Age at First Birth
Age at First Birth Number ofObservations Percentage
0 9 18
20 10 20
25 24 48
30 6 12
35 1 2
Total 50 100
Out of 50 patient 24 person (48%) of patient aged 25year had high
incidence of carcinoma breast.
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Parity
Out of 50 patient  ,most of the patient(76%)  belongs to 1 or 2 child
birth. Higher  the parity lesser the occurrence of carcinoma breast.
Parity Number of Observations Percentage
Nulliparous 9 18
Parity 1 10 20
Parity 2 19 38
Parity 3 6 12
Parity 4 3 6
?5 Parity 3 6
Total 50 100
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Breast Feeding
In my study most of the patient   having 2 or more children.7 of were
nulliparous and were not breast fed. Except 7 , all of the women breast fed.
Most of patients are 44% bolngs to breast fed for less than 12 months
Breast
Feeding in months
Number of
Observations Percentage
Nulliparous 9 18
1 to 12 22 44
13 to 24 14 28
25 to 36 5 10
Total 50 100
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Family History of Breast Cancer
Present
Absent
Family History of Breast Cancer
In my study about 2% of women having  positive family history.
Family History of
Breast Cancer
Number of
Observations Percentage
Present 1 2
Absent 49 98
Total 50 100
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18, 36%
Side of Breast Involved
Left
Right
Side of Breast Involved
In our study 32 patients (64%) presented with left sided cancer breast.
Side of Breast
Involved
Number of
Observations Percentage
Left 32 64
Right 18 36
Total 50 100
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Quadrant of Involvement
Quadrant of Involvement
Quadrant of
Involvement
Number of
Observations Percentage
UOQ 29 58
UIQ 5 10
LOQ 3 6
LIQ 3 6
Central 9 18
Multicentric 1 2
Total 50 100
In our study   29 patient (58%) presented with UOQ lump, followed by
central ,UIQ ,LIQ,LOQ and multicentric.  Most  commonest occurrence of
carcinoma breast is UOQ.
56
0
10
20
30
40
?2 cms2 2-5 cms2 >5 cms2
N
um
be
r o
f O
bs
er
va
ti
on
s
Size
Size of Tumour
Size of Tumour
Size of Tumour Number ofObservations Percentage
?2 cms2 3 6
2-5 cms2 34 68
>5 cms2 13 26
Total 50 100
In our study 3(6%) patient  presented with less  than 2cm,34(68%)
presented with 2-5cm sized tumour and 13(26%)  of them with >5 cm
tumour.
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Skin Involvement
Skin Involvement
In our study 4 of them having skin dimpling, 3 of them having  peau d’
orange and 1 of them  had skin tethering.
30  (60%) 0f the patients had lymph node at the time of presentation.
Lymphnode
involvement
No of
observer
Percentage
With LN 30 60
Without LN 20 40
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HPE Report
98% of the patients HPE report showed IDL.
HPE Report Number ofObservations Percentage
IDL 44 88
IDL+LVI 2 4
IDL++VE Margin 1 2
IDL+LVI +Ve
Margin 1 2
IDL+PERINODAL 1 2
SC 1 2
Total 50 100
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Clinical TNM
Staging
Number of
Observations Percentage
1A 2 4
11A 12 24
11B 20 40
111A 8 16
111B 8 16
Total 50 100
In our study 20 (40%) of the  patient  with stage 11B, followed by 12
(24%) with stage 11A, 8 (16%)  them with 111A and 8 (16%) stage 111B and
last comes stage 1A (4%).
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Treatment Given Number ofObservations Percentage
MRM+AC+HT 33 66
MRM+AC+RT+HT 4 8
NAC+MRM+AC+RT+HT 13 26
Total 50 100
In our study 13(26%) patient under gone NAC followed by MRM
then AC,RT,HTs.33(66%)  patient under gone MRM+AC+HT.4(8%)
undergone MRM+AC+RT+HT.
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Post-Operative Complications
Post-Operative Complications Number ofObservations Percentage
UE 38 76
SEROMA 7 14
WOUND GAPPING 1 2
ARM OEDEMA 1 2
FLAP NECROSIS 1 2
BRACHIAL NEURALGIA 1 2
WI 1 2
Total 50 100
In our study patient 7 (14%)  of them had  seroma, which is the  most
commonest  post operative  complication  noted.
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Hospital Stay Number ofObservations Percentage
? 10 days 39 78
> 10 days 11 22
Total 50 100
In our study patient 39 (78%)  of them stayed  less than 10 days , 11
(22%) patients stayed more than 10 days.
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DISCUSSION
SUMMARY & DISCUSSION WITH OTHER STUDIES
SUMMARY
1. The distribution of study population ranges from 21-80 years.
2. The most commonest presenting features in carcinoma breast is
lump(100%)
3. 52% of patients presented with less than 2 months duration of
symptoms.
4. In my study groups 50% of patients having DM and HT. This shows
both DM and HT are high risk of cancer breast.
5.  In my study the mean age of menarche is 12.49 years. This shows
earlier the menarche the more chance of malignancy.
6.  32 % of the study peoples were post menopausal age group.
7.   48% of patients have  first chid birth after 25 years.
8.  In my study about 76% of them have  1-2 child birth. This shows lesser
the parity higher the chance of malignancy.
9. About 2% of patients having positive family history.
10 . The most commonest side of involvement in my study is 64%.
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11. 58% of patients presented with lump in the UOQ. This is the most
commonest site of involvement in carcinoma breast.
12.  68% of presented with tumour size of 2-5 cm.
13.  60% of patient having  axillary  nodes at the time of presentation.
14. IDL is the most commonest histiopathological  type  ,it accounts for
98%.
15. In my study 40% 0f patient present with stage 11B and next comes
stage 111A.
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COMPARISION  WITH  OTHER STUDIES
Observations
in our study Percentages
Breast
Cancer-
India
scene –
Rakesh
Chopra
Study
Percentages
Age Class Intervals
21-30 3 6 24 3
31-40 8 16 136 18
41-50 23 46 246 33
51-60 11 22 195 26
61-70 4 8 111 15
71-80 1 2 40 5
Total 50 100 752 100
Clinical TNM Staging
1A 2 4 611 18
11A 12 24
1929
56
11B 20 40
111A 8 16
913
26
111B 8 16
Total 50 100 3453 100
Size of Tumour
?2 cms2 3 6 802 24
2-5 cms2 34 68 2111 63
>5 cms2 13 26 463 14
Total 50 100 3376 100
Lymph Node Status
Absent 20 40 1625 42
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In my  study  the mean  age  of   occurrence  of   operable  carcinoma
breast is 48.54 in comparing with the study  it is about 43.8.
Peak age of occurance of carcinoma breast is 41-50 years,in  our study
is about 46% in comparison to study group is 33%.
Stage wise distribution of my study is stage 1 is 4%, stage 11 is 64%,
stage 111 13% in comparison to other study group  are stage 1 is  8%,
stage11 is 56% ,stage 111 is 26%.
PRESENT 30 60 2261 58
Total 50 100 3886 100
HPE Report
IDL 44 88
3793 98
IDL+LVI 2 4
IDL++VE Margin 1 2
IDL+LVI +Ve
Margin 1 2
IDL+PERINODAL 1 2
SC 1 2 80 2
Total 50 100 3873 100
Receptor Status Distribution
Receptor –ve 28 56 59 47
ER-PR +ve 15 30 29 23
Her - 2 Neu +ve 7 14 37 30
Total 50 100 125 100
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Regarding the size of the tumour  in my study are  < 2cm-6%, 2-5cm
68% and >5 cm 32% ,when compared to other  study are <2 cm-8%, 2-5 cm-
56%, >5 cm 26%.
Nodal  status , in my study 60% of them nodal positive ,40% node
negative, when compared to other study mentioned above  node negative
42%,  node  positive  58%.
HPE report , in my study IDL accounts for 98%  , when comparing to
other study is about 98%.
Receptor status, in my study ER PR negative is 56% ,ERPR +ve  is
30% , HER 2 neu  is 14% , in comparison to other study it  is about 47%,
23%, and 30%.
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CONCLUSION
In my cross sectional prospective study 50 patient were subjected to
study.Following conclusion were attained.
1. Carcinoma is the most commonest cancer in females next to cancer
cervix.
2. Commonest age group involved are 41-50 years .Average age of
occurrence is 46 years.
3.  The disease is more   common in those patient with early menarche.
4.  Lesser the parity the chance of malignancy is more.  Nulliparous
women are more prone for  cancer breast.
5.  Painless  lump is the most commonest presentation  in carcinoma
breast  followed  by   pain.
6. Most commonly occurring in non vegetarian diet, those who are taking
high dietary fat..
7.  In my study 2%  of  patients  having  positive  family  history.
8.  Left breast is the commonest  side  of involvement  in cancer breast.
9. The most commonest site of ivolvement of carcinoma breast is Upper
outer quadrant.
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10. Most of the patient having  less than 5cm at the time of diagnosis.
11. Most commonest stage of presentation in my study was stage 11 and
stage 111
12. The most effective method of diagnosis in carcinoma breast is FNAC .
13. Infiltrating ductal carcinoma is the most commonest histological type.
14. Most commonest mode of treatment is multimodality management ie.
Surgery , chemotherapy ,hormonal therapy and radiotherapy.
15.  In  our  country  ,  because   of   poor   patient     complaints   and   less
accessibility of radiotherapy  and chemotherapy, all patients were
subjected to modified radical mastectomy  in early breast cancer
patient.
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ANNEXURES
PROFORMA
Name:                                                       IP No:
Age:                                                           Address:
Sex:                                                           Occupation:
DOA:                                                         Dod:
Presentation:
Complaints:
? Lump in the breast
? Pain
? Nipple discharge, nipple retraction
? Ulcer or nodules
? Swelling in the axilla
? Cough, Dyspnoea
? Chest pain, jaundice,
? Loss of appatite, loss of weight
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Past history:
? H/o DM/ HT
? H/o OCP intake,HRT intake
Personal history
Diet
Menstural history-age at menarche ,menstrual status
Obstetric history-No of childrens,Age at first child birth
Breast feeding histroy
Family history:H/o breast cancer in families
General examination:
Local examination:
Inspection:
Examination of affected breast:
Arms by the side , arm by the side , arm raised ,bending fowards
? Breast:  size, shape, swelling, position
? Skin over the breast: dilated veins ,dimpling, puckering, ulcer, nodules
? Nipple : size, shape ,retraction ,discharge, position
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? Areaola: Ulcer, cracks ,fissure
Palpation:
? Site , size ,shape ,surface , temp, tenderness, ,consistency ,margins.
? Mobility:
? Fixity to skin, breast tissue , pectoralis muscle ,chest wall.
? Examination of opposite breast:
? Examination of nodes:
Axilla, supraclavicular area
? Other system examination- CVS ,RS ,
? P/A examination,Spine and cranium, thyroid
? PV, PR
Diagnosis:
Investigation :
Routine investigation:
? Complete blood count
? Urine for sugar, protein,microscopy
? Blood-sugar ,urea , creatinine
Specific Investigation
? USG-Breast  ,axilla
? Mammography
? FNAC/ Tru-cut biopsy
? USG abdomen and pelvis
? Skeletal survey
? X-ray chest
? ECG
? LFT
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? Echo cardiogram
? Receptor status
Final Diagnosis:
Treatment given:
Histopathological report
Post operative condition
Follow up
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    Staging of disease Treatment givenPost Operative ComplicationHospital Stay
Lump Duration Pain
Nipple
Involvement
Skin
Involvement
Tumour Node Mets Stage
0<10 days , 1>10 days
1 Thrasammal 721/12 48 13 3 1 2 1 1 21 2 24 lump 1 0 0 0 1 1 6 0 LT Axilla node,fixed malig IDL ER,PR +ve T3 N2a M0 IIIA NAC+MRM+AC+RT+HT UE 0
2 Banumathy  884/12 65 12 3 1 2 0 1 18 2 12 lump 2 0 0 1 2 1 12 0 Rt Axllary  malig IDL HER2 +ve T3 N1 M 0 IIIA NAC+MRM+AC+RT+HT UE 0
3 Sarojadevi 79/13 60 16 3 3 2 0 1 22 1 10 lump 6 0 0 0 1 5 3 0 malig Secretory Carcinoma 0 T2 N1 M0 IIB MRM+AC+HT SEROMA 1
4 Vanaja 244/13 46 11 3 0 2 0 1 0 0 0 lump 2 0 0 0 2 1 4 0 malig IDL HER 2Ne +ve T2 N0 M0 IIA MRM+AC+HT UE 0
5 Kala 986/12 42 15 2 0 2 0 1 20 2 36 lump 2 0 1 2 1 5 15 2 LT Axilla malig IDL ER,PR +ve T4b N1 Mo III B NAC+MRM+AC+RT+HT WOUNDGAPPING 1
6 Suseela 396/13 52 11 3 2 2 0 1 19 2 6 lump 1 0 1 0 1 2 4 0 LT Axilla malig IDL+LVI +Ve margin ER,PR +ve T2 N1 Mo IIB MRM+AC+RT+HT UE 0
7 Shalinisalreen 591/13 65 13 3 3 2 0 1 23 5 6 lump 2 0 2 0 1 5 5 0 LT Axilla malig IDL 0 T2 N1 M0 IIB MRM+AC+HT UE 0
8 latha 6306 41 11 2 0 2 0 1 22 2 24 lump 3 0 0 0 1 1 4 0 malig IDL 0 T2 N0 M0 IIA MRM+AC+HT UE 0
9 karpagam 606/13 45 13 2 3 2 0 1 25 2 12 lump 12 0 0 1 1 4 4 2 malig IDL 0 T2 N0 M0 IIA MRM+AC+HT UE 0
10 panjalo 529/13 44 14 2 0 2 0 1 30 2 6 lump 6 0 0 0 1 1 5 0 Lt Axilla,mobile malig IDL+LVI 0 T2 N1 M0 IIB MRM+AC+HT UE 0
11 Saraswathy 634/13 66 15 3 0 1 0 1 26 3 36 lump 6 1 0 0 1 2 5 0 malig IDL ER,PR +ve T2 N0 M0 IIA MRM+AC+HT ARMOEDEMA 1
12 Dilsath 721/13 40 11 3 4 2 0 1 22 2 1 lump 8 1 0 0 1 4 4 0 Lt axilla, mobile malig IDL+PERINODAl HER2 +ve T2 N1 M0 IIB MRM+AC+RT+HT UE 0
13 Santhi 783/13 45 12 3 1 2 0 1 21 3 12 lump 12 0 1 0 2 5 5 0 malig IDL HER2 +ve T2 N0 M0 IIA MRM+AC+HT UE 0
14 Lakshmi 792/13 54 11 3 0 2 0 1 0 0 0 lump 0.5 0 0 0 2 5 1.5 0 malig IDL HER2 +ve T1 N0 M0 IA MRM+AC+RT+HT UE 0
15 Geetha 985/13 39 13 2 6 2 0 1 24 2 6 lump 6 0 0 0 2 1 4 0 malig IDL 0 T2 N0 M0 IIA MRM+AC+HT UE 0
16 Thulasi 1072 55 13 3 0 1 0 1 18 4 12 lump 12 0 0 0 1 1 5 0 malig IDL ER,PR +ve T2 N0 M0 IIA MRM+AC+HT UE 0
17 Ansaribeegam 835/13 55 13 3 2 2 0 1 21 1 12 lump 1 0 0 0 1 3 5 0 Lt Axilla,mobile malig IDL 0 T2 N1 M0 IIB MRM+AC+HT SEROMA 1
18 Senthur Kani 989/13 51 12 3 2 2 0 1 29 2 6 lump 1 0 0 0 2 4 7 0 Rt Axllary,mobile malig IDL ER,PR +ve T3 N1 M0 IIIA MRM+AC+RT+HT FLAP NECROSIS 1
19 Bala 990/13 39 11 2 0 2 0 1 0 0 0 lump 1 0 0 0 1 1 3 0 malig IDL 0 T2 N1 M0 IIB MRM+AC+HT UE 0
20 Lakshmi 1025/13 80 10 3 1 2 0 1 0 0 0 lump 2 0 0 0 1 1 4 0 malig IDL ER,PR +ve T2 N0 M0 IIA MRM+AC+HT UE 0
21 Sholia 1088/13 25 13 1 0 2 0 1 31 2 6 lump 2 0 0 0 2 1 4 0 malig IDL 0 T2 N0 Mo IIA MRM+AC+HT UE 0
22 Kalyani 1120/13 48 14 3 0 2 0 1 25 1 24 lump 6 0 0 0 1 1 4 0 Lt Axilla,Mobile malig IDL + LVI 0 T2 N1 M0 IIB MRM+AC+HT UE 0
23 Raja Lakshmi 1145/13 36 12 1 0 2 0 1 24 3 24 lump 2 0 0 0 1 5 4 0 malig Idl 0 T2 N0 M0 IIA MRM+AC+HT UE 0
24 Kairunisha 1177/13 59 12 3 0 2 0 1 20 7 24 lump 3 0 0 0 1 3 3 2 Lt Axila,Mobile mailg IDL ER,PR +ve T4b N1 M0 IIIB NAC+MRM+AC+RT UE 0
25 Victoria 1142/13 50 13 3 0 2 0 1 18 1 24 lump 1 0 0 0 1 1 6 0 malig IDL 0 T3 N0 M0 IIIA MRM+AC+HT UE 0
26 Sundari 3170 47 11 3 1 1 0 1 21 5 24  lump 1 0 0 0 1 1 5 0 Lt axilla,mobile malig IDL 0 T2 N1 M0 IIB MRM+AC+HT UE 0
27 Chinnaponnu 3780 50 12 3 0 2 0 0 0 0 0 lump 1 0 0 0 1 1 4 0 Lt axilla,mobile malig IDL 0 T2 N1 Mo IIB MRM+AC+HT UE 0
28 Thaslim Rahamani 4067 30 12 1 3 2 0 1 0 0 0 lump 1 0 0 0 1 1 8 0 Lt axilla,mobile malig IDL ER,PR +ve T3 N2a MO IIIA NAC+MRM+AC+RT+HT UE 0
29 Atchammal 4475 55 12 3 0 2 0 1 18 3 24 lump 2 1 0 0 2 1 6 0 RT axilla,mobile malig HER2 +ve T3 N1 M0 IIIA NAC+MRM+AC+RT+HT UE 0
30 varalakshmi 10345 37 11 1 3 2 0 1 22 2 36 lump 2 0 0 0 2 1 10 0 Rt axilla,fixed malig IDL ER,PR +ve T3 N2a M0 IIIA NAC+MRM+AC+RT+HT SEROMA 1
31 Vatchala 11779 69 14 3 1 2 0 1 18 3 24 lump 3 1 1 0 1 1 6 0 Rt axilla,fixed malig IDL ER,PR +ve T4b N2b Mo IIIB NAC+MRM+AC+RT+HT SEROMA 1
32 Narayini 12948 50 13 3 0 1 0 1 21 2 12 lump 2 0 0 0 1 3 5 0 RT axilla,mobile malig IDL 0 T2 N1 M0 IIB MRM+AC+HT UE 0
33 Ragini 12268 60 13 3 1 2 0 1 24 2 24 lump 12 1 1 2 1 1 2 1 Lt axilla,mobile malig IDL ER,PR +ve T4b N1 M0 IIIB NAC+MRM+AC+RT+HT UE 0
34 Mary 13663 48 12 3 1 2 0 1 21 1 6 lump 2 1 0 0 2 5 6 0 Rt axilla,mobile malig IDL 0 T3 N1 M0 IIIA MRM+AC+HT UE 0
35 Lakshmi 13666 50 13 3 1 2 0 1 22 2 24 lump 6 0 0 3 2 1 4 1 Rt axilla,mobile malig IDL 0 T2 N1 M0 IIB MRM+AC+RT WI 0
36 Rani 14593 60 12 3 1 2 0 1 22 4 6 lump 12 1 1 2 1 5 8 1 Lt axilla,fixed malig IDL ER,PR +ve T4b N1 M0 IIIB NAC+MRM+AC+RT+HT BRACHIAL NEURALGIA 1
37 Selvi 17898 48 12 3 0 2 0 1 21 3 36 lump 11 1 0 0 2 2 4 0 rt axilla,mobile malig IDL 0 T2 N1 M0  IIB MRM+AC+HT UE 0
38 Saroja 18439 50 13 3 0 2 0 1 20 1 24 lump 2 0 0 0 2 1 5 0 malig IDL 0 T2 N0 M0 IIA MRM+AC+HT UE 0
39 Muniyammal 12933 50 11 3 0 2 0 1 0 0 0 lump 0.5 0 1 0 1 5 5 0 Lt axilla,mobile malig IDL 0 T2 N1 M0 IIB MRM+AC+HT UE 0
40 Sarala 6679 41 12 2 0 2 0 1 22 1 12 lump 4 0 0 1 2 1 3 1 Rt axilla,mobile malig IDL HER 2Ne +ve T4a N2 M0 IIIB NAC+MRM+AC+RT+HT SEROMA 1
41 Vijaya 1355 49 11 2 0 2 0 1 20 2 12 lump 5 1 0 0 1 1 3 0 malig IDL 0 T2 N1 Mo IIB MRM+AC+HT UE 0
42 Shanthi 9889 48 14 2 1 2 0 1 21 1 12 lump 2 1 0 0 2 6 4 0 RT axilla,mobile malig IDL++VE Margin ER,PR +ve T2 N1 M0 IIB MRM+AC+RT SEROMA 1
43 Thangammal 2274 45 11 2 0 2 0 1 22 2 36 lump 3 0 0 0 1 1 5 0 Lt axilla, mobile malig IDL 0 T2 N1 M0 IIB MRM+AC+HT UE 0
44 Ponnammal 9917 55 15 3 0 1 0 1 0 0 0 lump 9 0 1 0 2 1 5 0 RT axilla,mobile mailg IDL 0 T2 N1 M0 IIB MRM+AC+HT UE 0
45 Padmavathy 394 48 11 2 3 2 0 1 26 1 12 lump 6 0 0 0 1 1 8 0 RT axilla,mobile malig IDL ER,PR +ve T3 N1 M0 IIIB NAC+MRM+AC+HT UE 0
46 selvi 21228 41 11 3 0 2 0 1 0 0 0 lump 4 0 0 0 1 1 2 0 malig IDL 0 T1 N0 M0 I MRM+AC+HT UE 0
47 Dharani 22855 40 17 3 0 2 0 1 22 2 24 lump 2 0 0 0 1 2 5 0 LT axill,mobile malig IDL 0 T2 N1 MO IIB MRM+AC+HT UE 0
48 Sumathy 4307 40 11 2 0 2 0 1 24 4 24 lump 4 0 0 0 1 1 3 0 mailg IDL 0 T2 N1 M0 IIB MRM+AC+HT SEROMA 1
49 sahayamari 1204 40 12 2 0 2 0 1 26 2 3 lump 4 1 1 1 2 2 6 1 RT axilla,modile malig IDL 0 T4b N1 M0 IIIB NAC+MRM+AC+RT UE 0
50 sudha 5552 26 12 1 0 2 0 1 27 1 12 lump 1 0 0 0 2 1 4 0 malig IDL 0 T2 N0 MO IIA MRM+AC+HT UE 0
1.size of tumour -<2,  2-5 ,>5cm
2.site- UOQ , UIQ ,LOQ ,LIQ, CENTRAL , MULTICENTRIC
3.Side -rt, lt
4.symptoms- lump, pain ,nipple retraction ,nipple discharge
5.Skin involvement- dimpling ,peaud' orange, skin tethering
6.duration of symptoms-< 2 months, 2-6 months ,7-12 months >1year
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